Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
211 results about "Beta-catenin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Catenin beta-1, also known as β-catenin, is a protein that in humans is encoded by the CTNNB1 gene. β-catenin is a dual function protein, involved in regulation and coordination of cell–cell adhesion and gene transcription. In humans, the CTNNB1 protein is encoded by the CTNNB1 gene. In Drosophila, the homologous protein is called armadillo. β-catenin is a subunit of the cadherin protein complex and acts as an intracellular signal transducer in the Wnt signaling pathway. It is a member of the catenin protein family and homologous to γ-catenin, also known as plakoglobin. Beta-catenin is widely expressed in many tissues. In cardiac muscle, beta-catenin localizes to adherens junctions in intercalated disc structures, which are critical for electrical and mechanical coupling between adjacent cardiomyocytes.
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
Owner:ALLERGAN SALES LLC
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS
Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions / disorders / diseases due to mutations or dysregulation of the Wnt pathway and / or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
Owner:BIOSPLICE THERAPEUTICS INC
Diagnosis and treatment of cervical cancer
InactiveUS20080113340A1Organic active ingredientsPeptide/protein ingredientsCervical lesionCervical cell
In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.
Owner:GEORGETOWN UNIV
Methods of identifying and isolating stem cells and cancer stem cells
InactiveUS7217568B2AlterationEasy to analyze and useMicrobiological testing/measurementArtificial cell constructsHematopoietic cellCancer cell
Methods and compositions are provided for the identification of stem cells and cancer stem cells. β-catenin is also identified as a target for the development of therapeutic moieties against hematopoietic tumors, i.e. leukemia and lymphoma cells, which may include screening assays directed at β-catenin, or members of the β-catenin signaling pathway. Cellular proliferation in hematopoietic cells can be altered by introducing stabilized β-catenin into a hematopoietic cell that is altered in its ability to undergo apoptosis but which is not fully transformed. The immortalized cells are useful in screening assays, and in the analysis of pathways by which hematopoietic cells undergo transformation.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Compositions and Methods for Treating and Diagnosing Cancer
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
Owner:MEREO BIOPHARMA 5 INC
Beta-catenin targeting peptides and uses thereof
InactiveUS20140005118A1Increase the helical character of peptidesIncrease productionPeptide/protein ingredientsPeptide preparation methodsDiseaseMedicine
The invention relates to β-catenin targeting peptides comprising an a-helical segment that are optionally stapled or stitched, and pharmaceutical compositions thereof. Uses of the inventive β-catenin targeting polypeptides including methods for treatment of disease, such as diseases associated with aberrant Wnt signaling, including cancer, are also provided.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Compositions and methods for treating and diagnosing cancer
ActiveUS8158758B2Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsBeta-cateninRSPO1
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
Owner:MEREO BIOPHARMA 5 INC
Generation of cardiomyocytes from human pluripotent stem cells
ActiveUS20130189785A1Artificial cell constructsSkeletal/connective tissue cellsProgenitorInduced pluripotent stem cell
Methods for generating high-yield, high-purity cardiomyocyte progenitors or cardiomyocytes from pluripotent cells are described. Wnt / β-catenin signaling is first activated in pluripotent cells, e.g., by inhibition of Gsk-3 to obtain a first population of cells. Wnt / β-catenin signaling is then inhibited in the first cell population to induce cardiogenesis under fully defined, growth factor free culture conditions.
Owner:WISCONSIN ALUMNI RES FOUND
Compositions and Methods for Treating and Diagnosing Cancer
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
Owner:ONCOMED PHARMA
BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER
ActiveUS20100152493A1Growth inhibitionPrevent cancerOrganic chemistryAntineoplastic agentsSolubilityCancer cell
It has been demanded to improve the poor solubility of curcumin to develop an anti-tumor compound capable of inhibiting the growth of various cancer cells at a low concentration. Thus, disclosed is a novel synthetic compound, a bis(arylmethylidene)acetone, which has both of an excellent anti-tumor activity and a chemo-preventive activity. A bis(arylmethylidene)acetone (i.e., a derivative having a curcumin skeleton) which is an anti-tumor compound and has a chemo-preventive activity is synthesized and screened. A derivative having enhanced anti-tumor activity and chemo-preventive activity can be synthesized.
Owner:SHIBATA HIROYUKI
Indazole-3-carboxamides and their use as wnt/beta-catenin signaling pathway inhibitors
Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions / disorders / diseases due to mutations or dysregulation of the Wnt pathway and / or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
Owner:BIOSPLICE THERAPEUTICS INC
RSPO Binding Agents and Uses Thereof
InactiveUS20130095116A1Inhibit tumor growthReduce frequencyAntibody mimetics/scaffoldsDisease diagnosisDiseaseBeta-catenin
The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and / or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
Owner:ONCOMED PHARMA
E. Coli Mediated Gene Silencing of Beta-Catenin
Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.
Owner:CEQUENT PHARMA
Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation
InactiveUS7563825B1Improve bindingIncreased proliferationBiocideOrganic chemistryBeta-cateninCell growth
Methods and agents are disclosed for modulating the interaction of β-catenin or γ-catenin with CBP or p300. Agents that increase the binding of CBP to β-catenin are associated with enhancing the β-catenin-related proliferation of adult stem cells, including hematopoietic stem cells, neural stem cells, skin stem cells, and pancreatic stem cells.
Owner:JW PHARMA CORP
Serum-free expansion of cells in culture
InactiveUS20070128669A1Enhanced interactionReduce interactionCompound screeningApoptosis detectionSerum igeSerum free
Methods and agents are disclosed for modulating the interaction of β-catenin or γ-catenin with CBP or p300. Agents that increase the binding of CBP to β-catenin are associated with enhancing the β-catenin-related proliferation of adult stem cells, including hematopoietic stem cells, neural stem cells, skin stem cells, and pancreatic stem cells, as well as embryonic stem cells.
Owner:JW PHARMA CORP
Pharmaceutical compositions to treat fibrosis
InactiveUS20130274215A1Prevents and reduces fibrosisBiocideCarbohydrate active ingredientsMedicineΒ catenin signaling
The present invention provides methods for the prevention, treatment and / or amelioration of fibrosis or fibrotic conditions. The present invention further provides small molecule inhibitors of Wnt- and TGF-p-mediated β-catenin signaling to prevent, treat and / or ameliorate fibrosis or fibrotic conditions. Kits comprising small molecule inhibitors of Wnt- and TGF-p-mediated β-catenin signaling and methods of identifying small molecule inhibitors of Wnt- and TGF-p-mediated β-catenin signaling are also provided.
Owner:FATE THERAPEUTICS
Bipartite T-cell factor (Tcf)-responsive promoter
InactiveUS20030228285A1High activityValid choiceBiocidePeptide/protein ingredientsBeta-cateninCancer therapy
The present invention is directed to methods and compositions for cancer therapy, particularly cancers resulting from a defective Wnt / beta-catenin signaling pathway. In specific embodiments, a T-cell factor (Tcf)-responsive promoter regulating expression of a therapeutic gene is administered to an individual having the cancer. In a specific embodiment, the Tcf-responsive promoter comprises a minimal CMV promoter and is present on an adenovirus vector. The promoter regulates expression of a therapeutic gene.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Progastrin inhibitors in the treatment of colon cancer
InactiveCN101460196ADigestive systemImmunoglobulins against hormonesConstitutively activeLymphatic Spread
The present invention relates to inhibitors of progastrin induced repression of ICAT for treating and / or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin / Tcf-4-mediated transcriptional pathway is constitutively active.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Diagnosis and treatment of cervical cancer
InactiveUS20070065810A1Reduce expressionReduced gene expressionPeptide/protein ingredientsTransferrinsCervical cellsCervical lesion
In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.
Owner:GEORGETOWN UNIV
Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and / or to stabilize β-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and / or compositions in the treatment of subjects having a neurological disease and / or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and / or Chir99021 in the treatment of subjects having a neurological disease and / or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.
Owner:MASSACHUSETTS INST OF TECH +1
Isoxazole derivatives and use thereof
Disclosed herein are isoxazole derivatives and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt / β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.
Owner:BIOPHARM
beta- and gamma-diketones and gamma-hydroxyketones as WNT/beta-catenin signaling pathway activators
ActiveUS8609717B2Increasing cell and tissue regenerationIncrease cell and tissue regenerationBiocideSenses disorderDiseaseBeta-catenin
Owner:BIOSPLICE THERAPEUTICS INC
Compounds for the modulation of beta-catenin expression
InactiveUS20090203137A1Facilitate entryOrganic active ingredientsSugar derivativesMedical disorderOligomer
The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
Owner:ENZON PHARM INC +1
Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells
Methods for generating high-yield, high-purity cardiomyocyte progenitors or cardiomyocytes from pluripotent cells are described. Wnt / β-catenin signaling is first activated in pluripotent cells, by, for example, inhibiting Gsk-3 to obtain a first population of cells. Wnt / β-catenin signaling is then inhibited in the first cell population to induce cardiogenesis. One or more of these steps is performed under defined, albumin-free culture conditions.
Owner:WISCONSIN ALUMNI RES FOUND
PTEN/Akt methods and compositions relating to BMP
ActiveUS20080248026A1Increase the number ofEfficient targetingImmunoglobulins against animals/humansEnzymologyPhosphorylationBeta-catenin
The present invention relates to a purified molecules, including antibodies, that bind specifically to murine β-catenin phosphorylated at amino acid position Serine552 and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.
Owner:STOWERS INST FOR MEDICAL RES +1
Compounds for the modulation of beta-catenin expression
InactiveUS20090005335A1Facilitate entryOrganic active ingredientsSugar derivativesMedical disorderOligomer
The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
Owner:SANTARIS PHARMA AS
Small-molecular compound combination for differentiated cell reprogramming, reagent kit and application of small-molecular compound combination
ActiveCN108060120AGood multiple germ layer multilineage differentiation potentialStable passageSkeletal/connective tissue cellsCell culture active agentsBeta-cateninReprogramming
The invention discloses a small-molecular compound combination for differentiated cell reprogramming, and a reagent kit and an application of the small-molecular compound combination. The small-molecular compound combination includes the following components: a TGF-beta inhibitor, a WNT / beta-catenin agonist, a cAMP agonist and a PKC inhibitor; furthermore, the small-molecular compound combinationalso includes at least one of an RAR agonist, a DNMT inhibitor, an HMT inhibitor, a histone demethylase inhibitor, ascorbic acid, a JNK inhibitor, an ROCK inhibitor and a lysine deacetylase inhibitor.Differentiated cells can be reprogrammed into mesenchymal stem cells by phased induction with the small-molecular compound combination, all steps can be subjected to precise quality control, and standardization operation and large-scale production are convenient. The method provided by the invention has wide donor sources, a patient himself can be used as a donor, and the mesenchymal stem cells needed for basic research, clinical treatment or tissue engineering production can be obtained in relatively short time.
Owner:YUNNAN JICI INSITUTE FOR REGENERATIVE MEDICINE CO LTD
Generation of cardiomyocytes from human pluripotent stem cells
ActiveUS8951798B2Artificial cell constructsSkeletal/connective tissue cellsProgenitorInduced pluripotent stem cell
Owner:WISCONSIN ALUMNI RES FOUND
Pilatory containing Wnt protein
InactiveCN101642563AQuick effectGood effectPeptide/protein ingredientsDermatological disorderBeta-cateninHair follicle
The invention provides a pilatory containing Wnt protein. The pilatory contains Wnt protein which enhances the growth of hair follicle by a Wnt / Beta-catenin signal channel. The pilatory leads the hairfollicle to have a growing period phenotype, and the hair follicle is transformed to the growing period from a stationary period. The pilatory has the advantages of obvious effect, fast effect, clearmechanism and the like and has important social and economical significance to develop drugs for enhancing the growth of hair.
Owner:ARMY MEDICAL UNIV
RNA Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (siNA)
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond expressed / synthetic to the modulation of PHD2 gene expression and / or activity, and / or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short inter-fering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsR-NA), micro-RNA (miRNA), and short hair-pin RNA (shRNA) molecules that are capa-ble of mediating or that mediate RNA inter-ference (RNAi) against PHD2 gene expres-sion.
Owner:SIRNA THERAPEUTICS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com